Guangzhou Baiyunshan Pharmaceutical Holdings (600332) Stock Price, Fundamentals & Analysis

What 600332 does

Guangzhou Baiyunshan Pharmaceutical Holdings (600332) operates in the pharmaceutical and healthcare sector on the Shanghai Stock Exchange. The company researches, develops, manufactures, and sells chemical drugs, traditional Chinese medicines, health products, and medical devices, while also running pharmaceutical wholesale and retail operations. Its business spans both domestic China and international markets. Within the broader healthcare landscape, it is sometimes compared with peers such as Jiangsu Hengrui Medicine (60276), WuXi AppTec (603259), and Fosun Pharmaceutical (600196).

Key numbers explained

• The current price of 19.39 CNY is the most recent trading price of one share.
• The trailing P/E ratio of 12.3 shows how much investors pay per unit of the company's last 12 months of earnings; a lower number can suggest the stock is priced more conservatively relative to earnings.
• The forward P/E ratio of 11.8 uses expected future earnings, which can reflect analyst estimates of growth or decline.
• The dividend yield of 3.87% indicates the annual dividend payment as a percentage of the current share price, a common way to compare income returns across stocks.
• The ex-dividend date of 10 sept. 2026 is the cutoff date; buying before this date is typically required to receive the next dividend.
• The beta of 0.17 suggests the stock has historically moved much less than the overall market, which is often interpreted as lower volatility.
• The price-to-book ratio of 0.81 means the stock trades below its book value per share, a metric some investors watch for potential value signals.

What to watch

Investors tracking Guangzhou Baiyunshan Pharmaceutical Holdings often monitor revenue trends, profit margins, and dividend consistency. The company's profit margin of 3.3% and operating margin of 2.2% reflect its cost structure and pricing power in the medical distribution industry. The debt-to-equity ratio of 47.8% provides a sense of how much the company relies on debt financing relative to shareholder equity. Because the stock is part of the CSI 300, broader index movements and sector rotations in Healthcare can influence its price. The 52-week price range of 19.3 – 27.5 and the year-over-year price change of -23.9% show the recent trading context, while the share of earnings paid out as dividends of 54% indicates the portion of profit returned to shareholders.